Krystal Biotech Inc
KRYS
查看详细走势图
285.970USD
+3.700+1.31%
收盘 02/02, 16:00（美东）报价延迟15分钟
8.29B总市值
41.46市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.31%
5天
+2.59%
1月
+15.82%
6月
+82.17%
今年开始到现在
+15.99%
1年
+79.02%
查看详细走势图
TradingKey Krystal Biotech Inc股票评分
单位: USD 更新时间: 2026-02-02操作建议
Krystal Biotech Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名3/393位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价290.82。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Krystal Biotech Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Krystal Biotech Inc亮点
亮点风险
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
分析师目标
根据
12
位分析师
买入
评级
290.818
目标均价
+4.15%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Krystal Biotech Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Krystal Biotech Inc简介
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
公司代码KRYS
公司Krystal Biotech Inc
CEOKrishnan (Krish S)
网址https://www.krystalbio.com/
相关品种
